Recombinant Human PD-L1/B7-H1 His-tag Protein, CF
Recombinant Human PD-L1/B7-H1 His-tag Protein, CF Summary
Why choose R&D Systems PD-L1 Protein?
- Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 90%.
- Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
- Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
- Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.
Find the Fc chimera PD-L1 protein here PD-L1 Fc
Visit Bio-Techne to explore other immune checkpoint proteins Immune Checkpoint Proteins
Product Specifications
Phe19-Thr239, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9049-B7
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 500 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
When Recombinant Human PD-L1 / B7-H1 is immobilized at 0.025 µg/mL, it binds to Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) with an ED50 of 0.05-0.3 µg/mL.
Reconstitution Calculator
Background: PD-L1/B7-H1
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), enothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).
- Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
- Dong, H. et al. (1999) Nat. Med. 5:1365.
- Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
- Tamura, H. et al. (2001) Blood 97:1809.
- Chen, L. et al. (2007) J. Immunol. 178:6634.
- Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
- Tsushima, F. et al. (2007) Blood 110:180.
- Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
- Cao, Y. et al. (2010) Cancer Res. 71:1235.
- Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
- Dong, H. et al. (2002) Nat. Med. 8:793.
- Azuma, T. et al. (2008) Blood 111:3635.
- Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
- Park, J.-J. et al. (2010) Blood 116:1291.
- Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
- Herold, M. et al. (2015) J. Immunol. 195:3584.
Citations for Recombinant Human PD-L1/B7-H1 His-tag Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
7
Citations: Showing 1 - 7
Filter your results:
Filter by:
-
Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition
Authors: T Phetphoung, A Malla, K Rattanapis, N Pisuttinus, N Damrongyot, K Joyjamras, P Chanvorach, T Phakham, T Wongtangpr, R Strasser, C Chaotham, W Phoolcharo
PLoS ONE, 2022-11-11;17(11):e0274737.
Species: Human
Sample Types: Protein
Applications: Bioassay -
Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-beta for Anticancer Immunotherapy
Authors: ZH Wu, N Li, ZZ Gao, G Chen, L Nie, YQ Zhou, MZ Jiang, Y Chen, J Chen, XF Mei, F Hu, HB Wang
Cancers, 2022-10-10;14(19):.
Species: Human
Sample Types: Antibody
Applications: Bioassay -
Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
Authors: R Le Biannic, R Magnez, F Klupsch, N Leleu-Chav, B Thiroux, M Tardy, H El Bouazza, X Dezitter, N Renault, G Vergoten, C Bailly, B Quesnel, X Thuru, R Millet
European Journal of Medicinal Chemistry, 2022-04-04;236(0):114343.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay -
PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-beta receptor I versus II
Authors: L Sun, Y Wang, X Wang, A Navarro-Co, S Ilyas, N Jalan-Sakr, C Gan, X Tu, Y Shi, K Tu, Q Liu, Z Lou, H Dong, AH Sharpe, VH Shah, N Kang
Cell Reports, 2022-02-08;38(6):110349.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
A human CD137�PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Authors: C Geuijen, P Tacken, LC Wang, R Klooster, PF van Loo, J Zhou, A Mondal, YB Liu, A Kramer, T Condamine, A Volgina, LJA Hendriks, H van der Ma, E Rovers, S Engels, F Fransen, R den Blanke, V Zondag-van, A Basmeleh, W Bartelink, A Kulkarni, W Marissen, CY Huang, L Hall, S Harvey, S Kim, M Martinez, S O'Brien, E Moon, S Albelda, C Kanellopou, S Stewart, H Nastri, ABH Bakker, P Scherle, T Logtenberg, G Hollis, J de Kruif, R Huber, PA Mayes, M Throsby
Nature Communications, 2021-07-21;12(1):4445.
Species: Human
Sample Types: Recombinant Protein
Applications: Surface Plasmon Resonance -
Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
Authors: JJ Park, EP Thi, VH Carpio, Y Bi, AG Cole, BD Dorsey, K Fan, T Harasym, CL Iott, S Kadhim, JH Kim, ACH Lee, D Nguyen, BS Paratala, R Qiu, A White, D Lakshminar, C Leo, RK Suto, R Rijnbrand, S Tang, MJ Sofia, CB Moore
Nature Communications, 2021-02-22;12(1):1222.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Rapid PD-L1 detection in tumors with PET using a highly specific peptide
Authors: Samit Chatterjee
Biochem. Biophys. Res. Commun, 2016-12-24;0(0):.
Applications: Bioassay
FAQs
-
Is there a linker between the PD-L1/B7-H1 protein and the His tag of Recombinant Human PD-L1/B7-H1 His-tag Protein, CF (Catalog # 9049-B7)?
The sequence for Recombinant Human PD-L1/B7-H1 His-tag Protein, CF (Catalog # 9049-B7) is Phe19-Thr239 (Accession # Q9NZQ7) fused directly to a C-terminal 6-His tag. This protein does not contain a linker sequence.
-
What are the differences between Recombinant Human PD-L1/B7-H1 His-tag Protein, CF (Catalog # 9049-B7) and Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?
Recombinant Human PD-L1/B7-H1 Protein, CF (Catalog # 9049-B7) consists of (Phe19-Thr239) from Accession # Q9NZQ7. It has a His tag but no Fc chimera. Activity for 9049-B7 is measured in a binding assay with Recombinant Human PD‑1 Fc Chimera (Catalog # 1086-PD). Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog 156-B7) consists of the same region (Phe19-Thr239), but instead of a His tag, it has a linker region and an Fc chimera. Activity for 156-B7 is assessed in a cell-based assay measuring IL-2 production by human T lymphocytes.
Reviews for Recombinant Human PD-L1/B7-H1 His-tag Protein, CF
Average Rating: 5 (Based on 12 Reviews)
Have you used Recombinant Human PD-L1/B7-H1 His-tag Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
